Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1CNS 1

Conditions

Pancreatic Neoplasms 4Urinary Bladder Neoplasms 3Prostatic Neoplasms 3Breast Neoplasms 3Ovarian Neoplasms 2Multiple Myeloma 2Lung Neoplasms 2Hematologic Neoplasms 2Wilms Tumor 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Thyroid Neoplasms 1Thrombocytosis 1Stomach Neoplasms 1Sarcoma, Synovial 1Sarcoma 1Rhabdomyosarcoma 1Rectal Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pleuropulmonary blastoma 1Neurofibrosarcoma 1Neuroblastoma 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Melanoma 1Lymphoma, Non-Hodgkin 1

Interventions

X-Rays 5Phantoms, Imaging 5Magnetic Resonance Spectroscopy 5Specimen Handling 4Nuclear Medicine Department, Hospital 4Melphalan 4Granulocyte Colony-Stimulating Factor 4Busulfan 4Filgrastim 3Cyclophosphamide 3Biopsy 3ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2palbociclib 2olaparib 2larotrectinib 2ivosidenib 2fludarabine 2ensartinib 2cabozantinib 2Vemurafenib 2Topotecan 2Thiotepa 2Temozolomide 2Stem Cell Transplantation 2Sirolimus 2Mesna 2LY3023414 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Rhabdomyosarcoma × Ado-Trastuzumab Emtansine × Genitourinary × Clear all
NCT02452554 2022-01-13

Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma

Children's Oncology Group

Phase 2 Completed
62 enrolled 15 charts
CNSGenitourinarySarcoma

Pleuropulmonary blastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Synovial, Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡